a randomized double.docVIP

A Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus GG for Abdominal Pain Disorders in Children A. Gawro?ska, P. Dziechciarz, A. Horvath, H. Szajewska Aliment Pharmacol Ther.?2007;25(2):177-184.? Summary and Background Summary Background:?Functional abdominal pain disorders (FAPD) are common in school-aged children; however, there is no reliable treatment.Aim:?To determine the efficacy of?Lactobacillus rhamnosus?GG (LGG) for treating FAPD in children.Methods:?A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double-blind, randomized controlled trial in which they received LGG (n?= 52), or placebo (n?= 52) for 4 weeks.Results:?For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05--6.6, number needed to treat (NNT) 7, 95% CI: 4--123). For children with IBS (n?= 37), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2--38, NNT 4, 95% CI: 2--36) and reduced frequency of pain (P?= 0.02), but not pain severity (P?= 0.10). For the FD group (n?= 20) and FAP group (n?= 47), no differences were found.Conclusion:?The LGG appears to moderately increase treatment success, particularly among children with IBS. Background Functional abdominal pain disorders (FAPD) are common, especially in school-aged children. Estimates of the incidence and prevalence vary depending on the diagnostic criteria and setting, but about 10–20%[1, 2]?of the school-aged population may be affected. According to the Rome II criteria,[3]?FAPD may be classified as functional dyspepsia (FD), irritable bowel syndrome (IBS), functional abdominal pain (FAP), abdominal migraine and aerophagia. Most recently, the Rome III c